Senior Medical Director, Portfolio Strategy, Medical Evidence Generation

Senior Medical Director, Portfolio Strategy, Medical Evidence Generation

The Senior Medical Director of Portfolio Strategy Medical Evidence Generation will be instrumental in shaping and executing a cohesive scientific and medical strategy across the entire franchise portfolio. Reporting to the Global Head of Alliance Immunology Portfolio Medical Strategy and Innovation, this individual will drive cross-functional and cross-therapeutic area alignment in evidence generation strategy, enhancing the value and impact of key data to inform strategic decisions and improve patient outcomes.

This role demands strong strategic leadership within medical affairs, a collaborative mindset across TAs and regions, and deep expertise in leveraging evidence generation to support disease modification strategies. The Senior Medical Director will partner closely with R&D, Medical, Commercial, and Market Access teams to ensure strategic alignment at global, regional, and local levels, while also engaging with external stakeholders, including key opinion leaders (KOLs) and healthcare decision-makers.

Success in this role requires superior expertise in evidence generation across TAs. a robust understanding of immunology, lifecycle management, stakeholder engagement, along with the ability to impact from strategic evidence generation across multiple therapeutic areas.

We are an innovative global healthcare company, committed to transforming the lives of people with immune challenges, rare diseases and blood disorders, cancers, and neurological disorders. From R&D to sales, our talented teams work together, revolutionizing treatment, continually improving products, understanding unmet needs, and connecting communities. We chase the miracles of science every single day, pursuing progress to make a real impact on millions of patients around the world.

Main Responsibilities

Portfolio Medical Strategy & Evidence Generation (40%)

• Design and implement a unified, portfolio-wide Integrated Evidence Generation Plan (iEGP) that aligns with Franchise strategies, supports the value proposition of the Alliance Immunology portfolio, and drives Lifecycle Management (LCM) priorities.
• Lead cross-therapeutic area (TA) innovation in evidence generation, including real-world evidence (RWE), by fostering collaboration across R&D, Medical Affairs, Commercial, and Market Access functions.
• Proactively identify data gaps and emerging opportunities within the evolving portfolio landscape, offering strategic recommendations to ensure optimal investment and impact-drive decision making for the franchise.
• Spearheading initiatives to enhance external engagement and data generation partnerships, and pilot key AI-enabled RWE platforms to support portfolio strategy.
• Monitor advancements in treatment paradigms, therapeutic landscapes, and competitive activity to reinforce and expand the franchise leadership in medical evidence generation.
• Collaborate closely with TAs, key markets and external partners to establish and operationalize a robust, competitive RWE framework that delivers timely, high-quality and impactful results aligned with core business objectives.

Cross-Functional & Regional Alignment (30%)

Impact Assessment & Execution Excellence (20%)

Portfolio & Stakeholder Engagement (10%)

About You

Requirements

Why Choose Us?

Sanofi Inc. and its U.S. affiliates are Equal Opportunity and Affirmative Action employers committed to a culturally diverse workforce. All qualified applicants will receive consideration for employment without regard to race; color; creed; religion; national origin; age; ancestry; nationality; marital, domestic partnership or civil union status; sex, gender, gender identity or expression; affectional or sexual orientation; disability; veteran or military status or liability for military status; domestic violence victim status; atypical cellular or blood trait; genetic information (including the refusal to submit to genetic testing) or any other characteristic protected by law.